Table 1 Demographic characteristics of 4752 patients
Overall | 2004-06 | 2007-09 | Pvalue | |
|---|---|---|---|---|
n = 4752 (%) | n = 2303 (%) | n = 2449 (%) | ||
Age (year) | ||||
Younger than 60 | 278 (5.9) | 154 (6.7) | 124 (5.1) | |
60-69 | 1423 (29.9) | 68.4 (29.7) | 739 (30.2) | |
70-79 | 2367 (49.8) | 1117 (48.5) | 1250 (51.0) | |
80 or older | 684 (14.4) | 348 (15.1) | 336 (13.7) | 0.036 |
PSA at diagnosis | ||||
10.0 or less | 2123 (44.7) | 963 (41.8) | 1160 (47.4) | |
10.1-20 | 1117 (23.5) | 554 (24.1) | 563 (23.0) | <0.001 |
Greater than 20 | 1512 (31.8) | 786 (34.1) | 726 (29.6) | |
Gleason score | ||||
2-6 | 1771 (37.3) | 906 (39.3) | 865 (35.3) | |
7 | 1614 (34.0) | 722 (31.4) | 892 (36.4) | |
8-10 | 1367 (28.8) | 675 (29.3) | 692 (28.3) | 0.001 |
Clinical T stage | ||||
T1 | 1605 (33.8) | 766 (33.3) | 839 (34.3) | |
T2 | 1919 (40.4) | 933 (40.5) | 986 (40.3) | |
T3 | 978 (20.6) | 489 (21.2) | 489 (20.0) | |
T4 | 250 (5.3) | 115 (5.0) | 135 (5.5) | 0.593 |
Clinical N stage | ||||
N0 | 4439 (93.4) | 2161 (93.8) | 2278 (93.0) | |
N1 | 313 (6.6) | 142 (6.2) | 171 (7.0) | 0.141 |
Clinical M stage | ||||
M0 | 4226 (88.9) | 2019 (87.7) | 2207 (90.1) | |
M1a | 17 (0.4) | 11 (0.5) | 6 (0.2) | |
M1b | 468 (9.8) | 257 (11.2) | 211 (8.6) | |
M1c | 41 (0.9) | 16 (0.7) | 25 (1.0) | 0.008 |
Risk classification | ||||
Low | 988 (20.8) | 474 (20.6) | 514 (21.0) | |
Intermediate | 1252 (26.3) | 561 (24.4) | 691 (28.2) | |
High | 1232 (25.9) | 626 (27.2) | 606 (24.7) | |
Very high | 657 (13.8) | 319 (13.9) | 338 (13.8) | |
Metastatic | 623 (13.1) | 323 (14.0) | 300 (12.3) | <0.001 |